Doubtful, they (FDA, and probably MSB) would want to see the...

Doubtful, they (FDA, and probably MSB) would want to see the data analysed for every measurable endpoint they can. So yes the primary endpoint is a simple binary response, are they alive or not, and this is the important one for this trial. But the secondary endpoints that can be recorded up to that 30 days will be looked at as well. It will take longer for the readout, but it's a good thing because the more measurable outcomes analysed, means more potential avenues for trials in future indications! More avenues, more revenues. Patience will pay off!
Links to why SI and FG said even if the interim readout shows overwhelming efficacy and Rem-L gets approved, MSB would prefer to continue doing the trial in its entirety, to gather the full data.